Inside informationEnglish
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Valneva SE
- Filed
- 09/04/2025, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 119126_20250409